Artelo Biosciences’ (ARTL) “Hold” Rating Reiterated at Maxim Group

Artelo Biosciences (NASDAQ:ARTL)‘s stock had its “hold” rating restated by stock analysts at Maxim Group in a report released on Wednesday,Benzinga reports.

Several other equities analysts have also weighed in on ARTL. D Boral Capital lowered Artelo Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 8th. D. Boral Capital reiterated a “hold” rating on shares of Artelo Biosciences in a report on Monday, September 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artelo Biosciences in a research report on Tuesday, November 11th. Finally, Wall Street Zen cut shares of Artelo Biosciences to a “strong sell” rating in a report on Saturday, August 9th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $24.00.

Artelo Biosciences Stock Performance

Shares of NASDAQ:ARTL traded down $0.05 during trading on Wednesday, hitting $1.84. 7,618 shares of the stock were exchanged, compared to its average volume of 275,690. The company has a market capitalization of $1.29 million, a price-to-earnings ratio of -0.09 and a beta of 1.23. The company’s fifty day simple moving average is $3.94 and its 200-day simple moving average is $7.41. Artelo Biosciences has a 1-year low of $1.66 and a 1-year high of $28.60.

Artelo Biosciences (NASDAQ:ARTL) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($3.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($3.15). On average, research analysts forecast that Artelo Biosciences will post -2.62 earnings per share for the current fiscal year.

About Artelo Biosciences

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.